Insulin Resistance Study

• Status: Suspended
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate how often patients with hepatitis C infection have abnormalities of sugar and fat utilization. Additionally we would like to find out if these abnormalities of sugar and fat utilization are common in other liver diseases, or related to being overweight.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Midwest Biomedical Research Foundation
• Treatments: Acetylcysteine; Insulin; N-monoacetylcystine

Criteria

Inclusion Criteria:

• Ability to give written consent

• HCV RNA PCR positive for 6 months

• Normal Hgb, WBC,Neutrophils

• Platelets of >/= 65,000

• Direct Bili, within 20% ULN

• Albumin >3

• Serum Creatinine <20% ULN

• TSH WNL

• AFP Exclusion Criteria:

• Women who are pregnant or breast-feeding

• No Thiazolidinedione, Metformin,unless required for the treatment of type II DM

• Hepatitis C of non-genotype 1,2,3

• Any other cause for liver disease other than chronic hepatitis C

• Hemoglobinopathies

• Evidence of advanced liver disease

• Previous organ transplant

• Severe psychiatric disorder

• Significant cardiovascular dysfunction within the past 12 months

• Poorly controlled diabetes mellitus

• Immunologically mediated disease

• Any medical condition requiring chronic systemic administration of steroids

• Evidence of an active or suspected cancer

• Substance abuse at the time of the study

• Known HIV

• Irritability or unwillingness to provide informed consent